<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>About Us | OryGyn Medical Devices</title>
  <link rel="icon" href="assets/favicon.ico">
</head>
<body>
  <header>
    <img src="assets/logo.png" alt="OryGyn Logo" width="150">
    <nav>
      <a href="index.html">Home</a> |
      <a href="about.html">About Us</a> |
      <a href="technology.html">Our Technology</a> |
      <a href="pipeline.html">Pipeline</a> |
      <a href="investors.html">Investors</a> |
      <a href="contact.html">Contact</a>
    </nav>
  </header>
  <main>
    <h1>About Us</h1>
    <h2>Company Management Team</h2>
    <ul>
      <li>
        <img src="assets/team_1.png" alt="Jeffrey T. Jensen" width="150">
        <strong>Jeffrey T. Jensen, MD, MPH</strong> – Founder and Chief Medical Officer. Dr. Jensen recently retired from OHSU as the Leon Speroff Endowed Professor and Vice Chair for Research in Obstetrics & Gynecology, directing the Women’s Health Research Unit. With over 35 years’ experience as a gynecologist and 25 years conducting women’s health clinical trials, he holds a part-time clinical appointment at OHSU and serves as Core Scientist at the Oregon National Primate Research Center (ONPRC). His foundational work, funded by the Bill & Melinda Gates Foundation, underpins this project. Dr. Jensen has consulted on gynecologic therapeutics development (including Skyla, Kyleena IUDs, Nexplanon, Nextellus, Annovera) for commercial entities and the Population Council.
      </li>
      <li>
        <img src="assets/team_4.png" alt="Holly Rockweiler" width="150">
        <strong>Holly Rockweiler</strong> – Chief Technology Officer. Co‑founder and CEO of Madorra, Holly has a background in biomedical engineering and biodesign. She earned her bachelor’s and master’s degrees at Washington University in St. Louis and worked at Boston Scientific, then joined Stanford Biodesign Fellowship, where her team addressed vaginal dryness leading to Madorra’s founding. She’s received SBIR grants from NSF and NIH.
      </li>
      <li>
        <img src="assets/team_3.png" alt="Jian Xin Guo" width="150">
        <strong>Jian Xin Guo, PhD</strong> – Chief Scientific Officer. Dr. Guo earned his PhD in polymer chemistry from McGill University and, since 2015, has led therapeutic foam formulation and delivery research at the Center for Regenerative Medicine at OHSU. Previously a scientist at Oregon Biomedical Engineering Institute, Oregon Biomedical Laser Center, Johnson & Johnson, and International Paper, he has collaborated with Dr. Jensen for five years on TSDS product development.
      </li>
      <li>
        <img src="assets/team_2.png" alt="Philberta Leung" width="150">
        <strong>Philberta Leung, PhD, PMP</strong> – Chief Operations Officer. Philberta holds a PhD in Neuroscience from Georgetown University and PMP certification from PMI. She managed collaborative research groups and biotech startups (Aronora, Omniox) before joining ONPRC in 2018. Her expertise in project management, database management, technology transfer, IP management, and budgeting ensures smooth coordination among OryGyn, Merge, and Medical Murray.
      </li>
    </ul>
    <h2>Business Advisory Group</h2>
    <ul>
      <li><strong>Sabrina Johnson</strong>, CEO of Daré. Ms. Johnson is a life sciences executive committed to advancing improvements in women’s healthcare. She founded Daré Bioscience in 2015 and has served as President, CEO and Board member since its inception and following its business combination with Cerulean Pharma in July 2017. Prior to that, she was President of Woman Care Global Trading from 2014–2015 and CFO/COO from 2013–2014. Daré Bioscience has expressed interest in acquiring the TSDS technology.</li>
      <li><strong>Brian A. Bernick, MD</strong>. Dr. Bernick is Chairman of the Board for Micron Biomedical, specializing in needleless drug delivery. With over 25 years in clinical medicine and business development, he oversees proof-of-concept through product launches and holds over 70 patents in drug therapies and devices. He founded TherapeuticsMD and led multiple FDA approvals (Annovera®, Bijuva®, Imvexxy®) and vitaCare Prescription Services.</li>
      <li><strong>Andrew Barofsky, JD, MBA</strong>. Mr. Barofsky is founder and CEO of RevMedx, focused on trauma care solutions (X-STAT®, Parabelt, XGauze). He’s outgoing Board Chair of the Oregon Bioscience Incubator and helped establish ObstetRX for postpartum hemorrhage. Dr. Jensen consulted on ObstetRx, now in clinical trial.</li>
    </ul>
    <h2>Scientific Advisory Group</h2>
    <ul>
      <li><strong>David Archer, MD</strong>, clinical trial consultant. Dr. Archer is Professor of Obstetrics and Gynecology and Director of the Clinical Research Center at Eastern Virginia Medical School. He’s part of the CONRAD program and Fellow of the American Congress of Obstetrics and Gynecology. He’s a member of the American Society for Reproductive Medicine, North American Menopause Society, and International Menopause Society. Past President of SREI and NAMS, he’s an international expert in gynecologic health and infertility.</li>
      <li><strong>Charles Carignan, MD</strong>, product development consultant. As CMO of Next Life Sciences, Dr. Carignan has served on FDA, CMS, WHO, UN, and USAID committees. He founded NinePoint Medical, BionX Medical, and SoniVie Inc., and is Executive Chairman of Cairdac and SamanTree Medical. Former EVP & CMO at Novasys Medical, CMO at Boston Scientific’s Endosurgery, and VP Clinical Research at Conceptus (Essure developer). An OPERM consultant since 2014.</li>
      <li><strong>Bob Katz, MS, MBA</strong>, product development consultant. As CEO of ForwardVue Pharm, he brings start-up experience and led ContraMed from pre-clinical to Phase 3 VeraCept IUD trial and acquisition by Sebela. OPERM consultant for four years, advising TSDS development.</li>
      <li><strong>Amy Thurmond, MD</strong>, clinical consultant. Dr. Thurmond, a women’s imaging radiologist, developed Fallopian Tube Recanalization for infertility and has numerous publications and awards. She collaborates with Dr. Jensen on HSG evaluations and TSDS testing.</li>
      <li><strong>Lisa Rarick, MD</strong>, regulatory consultant. Dr. Rarick is a board-certified OB/GYN and former FDA regulatory leader with 35 years in women’s health. She served as Medical Officer and Division Director at CDER before consulting on TSDS since 2018.</li>
      <li><strong>Don Waller, PhD</strong>, toxicology consultant. Professor emeritus of Pharmacology and Toxicology at University of Illinois Chicago, inventor of Phexi, and OPERM consultant since 2014 on TSDS product development.</li>
    </ul>
  </main>
  <footer><p>© 2025 OryGyn Medical Devices</p></footer>
</body>
</html>